Press Releases
AIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Additional commentary published discussing the potential of Ampligen and two other drugs OCALA, Fla., Aug. 20, 2024 -- AIM ImmunoTech Inc. (NYSE...
AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Continued execution across Ampligen® clinical development programs and growing body of positive data in multiple high-value indications - Company to host conference call and webcast today, August 16th at 8:30 AM ET OCALA, Fla., Aug. 16, 2024 -- AIM ImmunoTech...
AIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and Webcast
OCALA, Fla., Aug. 13, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), announced today that management will host a conference call and webcast to discuss the Company's Q2 2024 operational and financial results on Friday, August 16, 2024 at...
Stock Information
Recent SEC Filings
Corporate Presentation